Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PHASE II RANDOMIZED TRIAL OF 2- VS 5-FRACTION PROSTATE STEREOTACTIC ABLATIVE RADIOTHERAPY

NCT06835725 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT06835725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06835725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PHASE II RANDOMIZED TRIAL OF 2- VS 5-FRACTION PROSTATE STEREOTACTIC ABLATIVE RADIOTHERAPY
Lead sponsor
British Columbia Cancer Agency
Phase
Phase 2
Overall status
Recruiting
Start date
September 4, 2025
Completion date
April 30, 2033
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate ca